Does lycopene help with cancer? What the research does and doesn't show

The evidence doesn't support lycopene, in food or supplement form, as a treatment or a way to prevent any cancer. Most of the human data linking lycopene to a decreased cancer risk comes from diet, not a tested supplement, and is observational — an association, not a demonstrated effect of taking a pill. Where lycopene supplements have actually been tested in randomized trials, the results have mostly been null.

What the evidence doesn't support

It doesn't support lycopene supplementation as a treatment for existing prostate cancer: the one meta-analysis of actual supplementation trials in men already diagnosed found no significant overall effect on PSA. It doesn't support a claim that eating more lycopene, or supplementing with it, lowers colorectal cancer risk — the pooled result across 15 observational studies was not significant. It doesn't support the idea that higher lycopene levels protect against digestive-system cancers generally: a genetic (Mendelian randomization) analysis using UK Biobank data found no significant association there either. And it doesn't support treating a laboratory finding — lycopene killing cancer cells in a petri dish — as something that happens the same way inside a person; cell-culture exposures use concentrations and conditions that don't translate directly to a swallowed capsule.

What the trials found

The largest body of evidence is a 2017 systematic review and dose-response meta-analysis pooling 42 studies covering 43,851 prostate cancer cases among 692,012 participants, comparing people's dietary lycopene intake and blood lycopene levels against their prostate cancer risk. Both measures were associated with modestly lower risk (relative risk 0.88 for each), with roughly a 1% reduction in risk for every additional 2 mg of dietary lycopene in the dose-response analysis. This is observational evidence built from years of dietary habits and blood draws, not a trial where anyone was given lycopene and compared to a placebo group — it can't rule out that something else about a tomato-heavy diet, rather than lycopene itself, explains the association.

The closest thing to a direct supplementation test comes from a 2021 meta-analysis of six randomized controlled trials in men already diagnosed with non-metastatic prostate cancer, tracking PSA (a blood marker doctors monitor in prostate cancer) after lycopene supplementation. Overall, there was no significant effect on PSA (weighted mean difference -0.60 µg/L, 95% CI -2.01 to 0.81). A subgroup with higher starting PSA showed a reduction, but dose didn't predict the outcome across the six trials, and that subgroup result hasn't been confirmed on its own.

For colorectal cancer, a 2016 meta-analysis pooled 15 observational (case-control and cohort) studies comparing lycopene intake to colorectal cancer risk. The overall pooled result was not statistically significant (relative risk 0.94, 95% CI 0.80-1.10). A secondary analysis limited to studies reporting colon cancer specifically did find a significant inverse association (RR 0.88, 95% CI 0.81-0.96), but there was no dose-response relationship, and the authors rated the overall evidence quality very low using the GRADE system.

A different approach — Mendelian randomization, which uses genetic variants linked to a trait as a stand-in for long-term exposure — was used in a 2022 study drawing on UK Biobank data to test whether genetically predicted circulating lycopene was associated with digestive-system cancers: colorectal, gastric, pancreatic, liver and esophageal. It found no significant association (pooled odds ratio 0.93, 95% CI 0.81-1.08) between genetically predicted lycopene levels and risk of any of those cancers. This design sidesteps some of the confounding that affects diet-questionnaire studies, and it also came up null.

Separately, a laboratory study exposed two human prostate-cancer cell lines to lycopene in a dish. One line (androgen-responsive LNCaP cells) underwent a marked apoptotic (cell-death) response at very low lycopene concentrations after 48 hours; a second line (androgen-independent PC3 cells) resisted apoptosis even at much higher concentrations. Findings like this describe a biological mechanism worth studying further, not a demonstrated effect in a living person — cells in a culture dish aren't exposed to digestion, metabolism or the rest of a body's systems, and no human trial has reproduced this result as a clinical outcome.

Study	Design	Population / dose	Finding
Rowles et al., 2017	Meta-analysis, 42 observational studies	692,012 people; dietary & blood lycopene	Higher intake associated with decreased prostate cancer risk (RR 0.88)
Sadeghian et al., 2021	Meta-analysis, 6 RCTs	Men with non-metastatic prostate cancer	No significant overall effect on PSA
Wang et al., 2016	Meta-analysis, 15 observational studies	Mixed adult populations	No significant overall colorectal cancer association; colon-specific subgroup significant, very low quality evidence
Yin et al., 2022	Mendelian randomization	UK Biobank genetic data	No significant association with digestive-system cancers
Ivanov et al., 2007	In-vitro, prostate cancer cell lines	Cell-culture exposure, not a human dose	Apoptosis induced in one of two cell lines

Questions people ask

Can lycopene kill cancer cells?

In a laboratory dish, yes for at least one prostate-cancer cell line: a cell-culture study found lycopene exposure triggered apoptosis in LNCaP cells at very low concentrations, though a second cell line resisted it. That's a mechanism observed in cultured cells, not evidence that taking a lycopene supplement kills cancer cells inside a person.

Does lycopene cause cancer?

We found no evidence that lycopene causes cancer. The Mendelian randomization study above, using genetic data as a proxy for lifelong lycopene exposure, found no increased risk of digestive-system cancers associated with higher genetically predicted lycopene.

Does lycopene prevent skin cancer?

We found no trial testing lycopene supplementation against skin cancer risk specifically. A separate 2005 trial found about 10 mg of lycopene a day reduced UV-induced skin reddening (sunburn response) after 12 weeks — a different outcome from skin cancer prevention, and not evidence for it.

Is lycopene good for prostate cancer prevention?

The evidence that exists is observational: people who eat more lycopene-containing foods tend to have somewhat decreased prostate cancer rates. That's a diet association, not a demonstrated effect of a supplement — no trial has tested whether taking a lycopene pill lowers a healthy person's risk of developing prostate cancer.

When to talk to a doctor

Anyone with a cancer diagnosis, a family history of cancer, or concerns about cancer screening should talk to their doctor or oncologist rather than a supplement label. Lycopene is not a treatment or prevention for prostate, colorectal or any other cancer, and nothing in the evidence above supports using it as a substitute for the screening, monitoring or treatment a doctor recommends.

Related reading: lycopene benefits: what the research does and doesn't show, what is lycopene, and lycopene: what the research does and doesn't show.